RGEN Stock Overview
Develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Repligen Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$148.18 |
| 52 Week High | US$211.13 |
| 52 Week Low | US$110.45 |
| Beta | 1.03 |
| 1 Month Change | -6.43% |
| 3 Month Change | -24.21% |
| 1 Year Change | -11.41% |
| 3 Year Change | -16.65% |
| 5 Year Change | 96.73% |
| Change since IPO | 1,345.66% |
Recent News & Updates
Repligen Stock: Still Quite Overvalued
May 30Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models
May 03
Recent updates
Repligen Stock: Still Quite Overvalued
May 30Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models
May 03Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Apr 30Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price
Dec 19What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?
Nov 01Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?
Sep 29Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade
Aug 09Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?
Jul 03With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case
Jun 19Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)
May 23Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Apr 11Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?
Mar 28We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease
Mar 08Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Feb 20Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Jan 10Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?
Dec 28Is Repligen (NASDAQ:RGEN) A Risky Investment?
Oct 03Repligen: Now Best Biotech Nearby Cap-Gain Prospect
Sep 27Repligen partners with DRS daylight solutions
Sep 19When Should You Buy Repligen Corporation (NASDAQ:RGEN)?
Sep 19Shareholder Returns
| RGEN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -6.3% | -4.2% | -1.2% |
| 1Y | -11.4% | 2.5% | 21.5% |
Return vs Industry: RGEN underperformed the US Life Sciences industry which returned 2.5% over the past year.
Return vs Market: RGEN underperformed the US Market which returned 21.5% over the past year.
Price Volatility
| RGEN volatility | |
|---|---|
| RGEN Average Weekly Movement | 5.3% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RGEN's share price has been volatile over the past 3 months.
Volatility Over Time: RGEN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 1,783 | Tony Hunt | www.repligen.com |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
Repligen Corporation Fundamentals Summary
| RGEN fundamental statistics | |
|---|---|
| Market cap | US$8.28b |
| Earnings (TTM) | US$14.84m |
| Revenue (TTM) | US$607.45m |
557.9x
P/E Ratio13.6x
P/S RatioIs RGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGEN income statement (TTM) | |
|---|---|
| Revenue | US$607.45m |
| Cost of Revenue | US$318.08m |
| Gross Profit | US$289.37m |
| Other Expenses | US$274.53m |
| Earnings | US$14.84m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.27 |
| Gross Margin | 47.64% |
| Net Profit Margin | 2.44% |
| Debt/Equity Ratio | 29.6% |
How did RGEN perform over the long term?
See historical performance and comparison